Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue.

Oncotarget·2025

Same author

Intraoperative Guidance of Pancreatic Cancer Resection Using a Toll-like Receptor 2-Targeted Fluorescence Molecular Imaging Agent.

Cancer research communications·2024

Same author

Eco-evolutionary Guided Pathomics Analysis to Predict DCIS Upstaging.

bioRxiv : the preprint server for biology·2024

Same author

L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy.

Biomedicines·2024

Same author

L-DOS47 enhances response to immunotherapy in pancreatic cancer tumor.

bioRxiv : the preprint server for biology·2023

Same author

Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI.

Contrast media & molecular imaging·2023

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Molecular imaging and targeted therapies.

David L Morse¹, Robert J Gillies

¹H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive SRB-2, Tampa, FL 33612, United States.

Biochemical Pharmacology

|April 20, 2010

Summary

Biomarkers, especially imaging biomarkers, can significantly reduce clinical trial costs by identifying patients likely to respond to targeted therapies. This review explores their role in predicting treatment response and optimizing drug development.

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Molecular Imaging to Target Transplanted Muscle Progenitor Cells

Molecular Imaging to Target Transplanted Muscle Progenitor Cells

Published on: March 27, 2013

Related Experiment Videos

Last Updated: Jun 13, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Molecular Imaging to Target Transplanted Muscle Progenitor Cells

Molecular Imaging to Target Transplanted Muscle Progenitor Cells

Published on: March 27, 2013

Area of Science:

Biomedical Imaging
Pharmacology
Clinical Trial Design

Background:

Targeted therapies and imaging agents are increasing, leading to higher clinical trial costs.
Biomarkers can enhance clinical trials by predicting patient response to targeted agents.
Predictive biomarkers are crucial for patient segmentation in drug development.

Purpose of the Study:

To review the role of functional and molecular imaging in predicting therapy response.
To explore the pros and cons of targeting intracellular versus extracellular markers.
To discuss attributes of useful targets and methods for their identification and validation.

Main Methods:

Review of literature on functional and molecular imaging biomarkers.
Analysis of biomarker utility in patient segmentation for targeted therapies.
Discussion of target identification and validation strategies.

Main Results:

Predictive biomarkers, particularly imaging biomarkers, can enrich clinical trial populations.
Non-invasive imaging biomarkers offer advantages for longitudinal monitoring.
Targeting specific biomarkers can improve the efficiency of drug development.

Conclusions:

Biomarkers are essential for optimizing targeted therapy development and clinical trials.
Imaging biomarkers provide a non-invasive method for predicting and monitoring treatment response.
Careful selection and validation of targets are critical for successful biomarker application.